GSK forges novel R&D partnerships with CDRD

GlaxoSmithKline (GSK) has entered into a two-part R&D collaboration with the Centre for Drug Research and Development (CDRD) and its commercial arm CDRD Ventures Inc (CVI). The novel agreement will see GSK support early-stage projects through CDRD via the GSK-CDRD Innovation Fund. These projects will engage academic investigators at CDRD's affiliated institutions or hospital-based research centres. Another fund in conjunction with CVI will move later-stage projects further toward commercialization. GSK will partially fund projects conducted or managed by CVI. The GSK collaboration is the latest industry partnership forged by CDRD. It also has deals with Roche, Pfizer Canada and Johnson & Johnson (US) (R$, February 27/12)….